open access
Efficacy of the greater occipital nerve block in recurrent migraine type headaches
Affiliations- Department of Anesthesiology, Abant Izzet Baysal University School of Medicine, Bolu, Türkiye
- Department of Neurosurgery, Abant Izzet Baysal University School of Medicine, Bolu, Türkiye
- Department of Radiology, Abant Izzet Baysal University School of Medicine, Bolu, Türkiye
- Department of Neurosurgery, Reyap Hospital, Tekirdag, Türkiye
open access
Abstract
We aimed to evaluate six months of results following repeated GON blocks.
MethodsWe evaluated the results from GON block performed on 60 patients. Briefly, we applied a standard 2mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks. We recorded the Visual Analog Scale (VAS) scores, the number of migraine attacks and the Migraine Disability Assessment Questionnaire (MIDAS) scores. The study subjects were not allowed to use medication for prophylaxis, and Ibuprofen (400mg, 1200mg at maximum) was prescribed for any migraine attacks.
ResultsThe initial mean number of attacks per month before starting treatment was 8.33+2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined to 1.47 in 3rd, and was 1.50 in the 6th month. The individual month values were found to be significant, and were listed respectively as, 1st month: 3.95+2.52, 2nd month: 3.23+1.82, 3rd month: 2.60+1.90, 4th month: 2.68+2.10, 5th month: 2.58+1.90 and 6th month: 2.58+1.90. The mean VAS scores were recorded as follows for each month: 6.28±1.24, 3.13±0.97, 2.55±1.19, 2.35±1.26, 2.38±1.20 and 2.48±1.30, respectively. This difference was noted to be statistically significant. No difference regarding the efficacy of the treatment was determined when the results were compared across age groups.
ConclusionWe assume that GON blockage with 2mL of 0.5% Bupivacaine can be a supportive treatment in migraine treatment, with no serious adverse effects reported.
Abstract
We aimed to evaluate six months of results following repeated GON blocks.
MethodsWe evaluated the results from GON block performed on 60 patients. Briefly, we applied a standard 2mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks. We recorded the Visual Analog Scale (VAS) scores, the number of migraine attacks and the Migraine Disability Assessment Questionnaire (MIDAS) scores. The study subjects were not allowed to use medication for prophylaxis, and Ibuprofen (400mg, 1200mg at maximum) was prescribed for any migraine attacks.
ResultsThe initial mean number of attacks per month before starting treatment was 8.33+2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined to 1.47 in 3rd, and was 1.50 in the 6th month. The individual month values were found to be significant, and were listed respectively as, 1st month: 3.95+2.52, 2nd month: 3.23+1.82, 3rd month: 2.60+1.90, 4th month: 2.68+2.10, 5th month: 2.58+1.90 and 6th month: 2.58+1.90. The mean VAS scores were recorded as follows for each month: 6.28±1.24, 3.13±0.97, 2.55±1.19, 2.35±1.26, 2.38±1.20 and 2.48±1.30, respectively. This difference was noted to be statistically significant. No difference regarding the efficacy of the treatment was determined when the results were compared across age groups.
ConclusionWe assume that GON blockage with 2mL of 0.5% Bupivacaine can be a supportive treatment in migraine treatment, with no serious adverse effects reported.
Keywords
Bupivacaine, Migraine, Migraine Disability Assessment Questionnaire, Occipital nerve block, Visual Analog Scale
About this articleTitle
Efficacy of the greater occipital nerve block in recurrent migraine type headaches
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
151-154
Page views
305
Article views/downloads
406
DOI
10.1016/j.pjnns.2016.01.015
Bibliographic record
Neurol Neurochir Pol 2016;50(3):151-154.
Keywords
Bupivacaine
Migraine
Migraine Disability Assessment Questionnaire
Occipital nerve block
Visual Analog Scale
Authors
Korgun Okmen
Yasar Dagistan
Emine Dagistan
Necati Kaplan
Emre Cancan
